Research Paper Volume 12, Issue 20 pp 20254—20267
Development and validation of an immune and stromal prognostic signature in uveal melanoma to guide clinical therapy
Figure 8. Differential putative chemotherapeutic and immunotherapeutic response. (A–G) The box plots of the estimated IC50 for the most sensitive chemotherapeutic drugs. (H) Submap analysis manifested that high risk group could be more sensitive to the programmed cell death protein 1 inhibitor (Bonferroni-corrected P = 0.02). *** P < 0.001.